Standard BioTools
LAB
89 hedge funds and large institutions have $509M invested in Standard BioTools in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
32% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $899K
31% more capital invested
Capital invested by funds: $389M → $509M (+$120M)
11% more funds holding
Funds holding: 80 → 89 (+9)
Top Buyers
Top Sellers
LAB Hedge Fund Activity: Q3 2013 in Review
89 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2013, worth a combined $509M — up 31% from $389M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LAB positions and 7 closed out — a net gain of 9 holders — while 37 added to existing stakes and 25 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $13.8M. The largest seller was Fort Washington Investment Advisors, cutting an estimated $6.04M.
- 89 institutional investors held Standard BioTools (LAB) as of Q3 2013, up from 80 in Q2 2013.
- Funds reported $509M of Standard BioTools stock for Q3 2013, up 31% quarter-over-quarter.
- 16 funds opened new Standard BioTools positions in Q3 2013 and 7 closed out, a net change of +9 holders.
- The largest Standard BioTools buyer in Q3 2013 was Lord, Abbett & Co, an estimated $13.8M added.
- The largest Standard BioTools seller in Q3 2013 was Fort Washington Investment Advisors, an estimated $6.04M sold.
Based on aggregated 13F filings for Q3 2013.